Devicemakers relying on overseas sales; Case against maker of hernia repair patches goes to court;

> Medical device makers are relying on overseas sales to drive growth as the U.S. economy struggles to right itself, a trend likely to persist as big U.S. markets for heart products and other technologies mature. Report

> The first of more than 3,000 lawsuits accusing a Rhode Island company of manufacturing and marketing faulty hernia repair patches went to trial Monday in U.S. District Court. Story

> Senate votes down measure to kill medical device tax. Story

> A study published in Annals of Surgery has shown that Medtronic's InterStim Therapy can be used to treat fecal incontinence. Item

> Dr. Christian Spaulding is leaving his post as director of the cath lab at Cochin Hospital in Paris to become the new worldwide vice president of medical affairs for the Johnson & Johnson subsidiary Cordis, the company announced Monday. Article

> A flexible, implantable medical device about the size of a nickel treats abnormal rhythms by wrapping around the heart to produce a high density map of electrical activity. Story

> Roche Diagnostics announced that the FDA has granted CLIA-waived status to the CoaguChek XS Plus system, a point-of-care anticoagulation monitor that offers connectivity and data management tools to help healthcare professionals manage PT/INR (blood clotting time) testing. Release

> If a proposal to allocate radio spectrum for a wireless medical network is approved, many patients may no longer need to travel to a health care facility to be tethered to large machines that monitor their health. Report

And Finally... Australia on Tuesday unveiled a prototype bionic eye designed to restore sight to those with failing vision which supporters hope could be the biggest breakthrough since the Braille alphabet. Story

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.